Technical Analysis for FDMT - 4D Molecular Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Calm After Storm | Range Contraction | -0.92% | |
| Wide Bands | Range Expansion | -0.92% | |
| Calm After Storm | Range Contraction | 2.29% | |
| Wide Bands | Range Expansion | 2.29% | |
| Oversold Stochastic | Weakness | 2.29% | |
| Stochastic Buy Signal | Bullish | 2.29% | |
| Lower Bollinger Band Walk | Weakness | 2.29% |
| Alert | Time |
|---|---|
| Down 1% | about 8 hours ago |
| 60 Minute Opening Range Breakdown | about 8 hours ago |
| Possible NR7 | about 9 hours ago |
| Possible Inside Day | about 9 hours ago |
| 10 DMA Resistance | about 13 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 08/07/2024
4D Molecular Therapeutics, Inc. Description
4DMT is a clinical-stage gene therapy company pioneering the development of product candidates using targeted and evolved AAV vectors. 4DMT seeks to unlock the full potential of gene therapy using its platform, Therapeutic Vector Evolution, which combines the power of directed evolution with approximately one billion synthetic capsid sequences to invent evolved vectors for use in targeted gene therapy products. The company is initially focused in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The 4DMT targeted and evolved vectors are invented with the goal of being delivered through clinically routine, well-tolerated and minimally invasive routes of administration, transducing diseased cells in target tissues efficiently, having reduced immunogenicity and, where relevant, having resistance to pre-existing antibodies. 4DMT is currently conducting three clinical trials: 4D-125 is in a Phase 1/2 clinical trial for XLRP, 4D-110 is in a Phase 1 clinical trial for choroideremia and 4D-310 is in a Phase 1/2 clinical trial for Fabry disease.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Life Sciences Biology Emerging Technologies Antibodies Molecular Biology Gene Therapy Medical Genetics Gene Delivery Fabry Disease Gene Therapy Products Choroideremia Gene Therapy Of The Human Retina
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 36.25 |
| 52 Week Low | 9.44 |
| Average Volume | 975,696 |
| 200-Day Moving Average | 21.44 |
| 50-Day Moving Average | 22.75 |
| 20-Day Moving Average | 20.83 |
| 10-Day Moving Average | 19.13 |
| Average True Range | 2.05 |
| RSI (14) | 41.86 |
| ADX | 20.59 |
| +DI | 26.58 |
| -DI | 31.10 |
| Chandelier Exit (Long, 3 ATRs) | 22.77 |
| Chandelier Exit (Short, 3 ATRs) | 20.30 |
| Upper Bollinger Bands | 28.18 |
| Lower Bollinger Band | 13.47 |
| Percent B (%b) | 0.33 |
| BandWidth | 70.64 |
| MACD Line | -1.50 |
| MACD Signal Line | -1.15 |
| MACD Histogram | -0.3462 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 20.02 | ||||
| Resistance 3 (R3) | 20.16 | 19.74 | 19.74 | ||
| Resistance 2 (R2) | 19.74 | 19.32 | 19.67 | 19.64 | |
| Resistance 1 (R1) | 19.05 | 19.06 | 18.84 | 18.91 | 19.55 |
| Pivot Point | 18.63 | 18.63 | 18.53 | 18.56 | 18.63 |
| Support 1 (S1) | 17.94 | 18.21 | 17.73 | 17.80 | 17.15 |
| Support 2 (S2) | 17.52 | 17.95 | 17.45 | 17.06 | |
| Support 3 (S3) | 16.83 | 17.52 | 16.96 | ||
| Support 4 (S4) | 16.69 |
